Sankala Group
REGN icon

Sankala Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Sankala Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$48.5K Hold
64
– – 0.03% 245
2026
Q2 		$52.2K Hold
64
– – 0.03% 246
2026
Q1 		$48K Sell
64
-1
-2% -$766 0.04% 235
2025
Q4 		$50.8K Buy
+65
New +$44.1K 0.04% 228

Other funds holding REGN

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $77.1B AUM 11.99% 1-Year Est. Return
Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Sankala Group's REGN Position: Q3 2026 in Review

Sankala Group held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2026 at 64 shares worth $48.5K. The position accounts for 0.03% of the portfolio, ranked #245.

Sankala Group first reported a position in REGN in Q4 2025 and has held it in 4 quarters since. The position peaked at $52.2K in Q2 2026. 1,065 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Sankala Group held 64 shares of Regeneron Pharmaceuticals worth $48.5K as of Q3 2026.
  • Sankala Group left its Regeneron Pharmaceuticals share count unchanged in Q3 2026.
  • Regeneron Pharmaceuticals made up 0.03% of Sankala Group's portfolio in Q3 2026, its #245 holding.
  • Sankala Group first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Sankala Group's Regeneron Pharmaceuticals position peaked at $52.2K in Q2 2026.
  • 1,065 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Sankala Group's 13F filing for Q3 2026, filed 9 Nov 2026.